Analyst Ratings — September 23, 2026
Today’s Canadian and U.S. analyst ratings point to a selective market outlook. Analysts remain bullish on AI infrastructure, semiconductors, parts of healthcare and several Canadian mining stocks, with target increases supporting those areas. The picture is less favourable for U.S. retailers, homebuilders, banks and some software companies, where target cuts and downgrades suggest pressure from borrowing costs and uneven demand. Canadian resource ratings are also mixed, particularly among precious metals producers, while energy attracts interest on both sides of the border. Overall, analysts still see opportunities, but the split in revisions suggests a market driven by specific sectors and company results rather than a broad advance.
Canadian Analyst Ratings —
AGF-Management Ltd. (AGF-B:CA): TD Securities maintained its Buy rating with a $23.00 target price.
Americas Gold and Silver Corporation (USA:CA): TD Securities maintained its Buy rating with an $8.50 target price.
Aya Gold & Silver Inc. (AYA:CA): Scotiabank maintained its Outperform rating with a $46.00 target price.
BCE-Inc. (BCE:CA): Scotiabank maintained its Outperform rating with a $40.00 target price.
Blue Moon Metals Inc. (MOON:CA): Scotiabank maintained its Outperform rating with a $14.00 target price.
Canadian National Railway Co. (CNR:CA): National Bank lowered its target price to $190.00 from $192.00 while maintaining its Sector Perform rating.
Canadian Pacific Kansas City Ltd. (CP:CA): National Bank maintained its Outperform rating with a $140.00 target price.
Capstone Copper Corp. (CS:CA): Scotiabank maintained its Outperform rating with a $19.00 target price.
Coelacanth Energy Inc. (CEI:CA): RBC Capital initiated coverage with a Sector Perform rating and a $0.80 target price.
Coveo Solutions Inc. (CVO:CA): TD Securities maintained its Buy rating with a $7.00 target price.
Elemental Royalty Corp. (ELE:CA): Canaccord Genuity raised its target price to $36.00 from $30.00; no rating was supplied.
Elemental Royalty Corp. (ELE:CA): Raymond James raised its target price to $36.00 from $33.00 while maintaining its Outperform rating.
Endeavour Silver Corp. (EDR:CA): CIBC downgraded the stock to Neutral from Outperformer and lowered its target price to $20.00 from $25.00.
Ero Copper Corp. (ERO:CA): CIBC raised its target price to $56.00 from $52.00 while maintaining its Neutral rating.
Ero Copper Corp. (ERO:CA): Scotiabank maintained its Outperform rating with a $55.00 target price.
Founders Metals Inc. (FDR:CA): BMO raised its target price to $9.00 from $8.00; no rating was supplied.
Gran Tierra Energy Inc. (GTE:CA): Roth MKM raised its target price to $18.50 from $17.50; no rating was supplied.
Hemlo Mining Corp. (HMCC:CA): Scotiabank maintained its Outperform rating with a $9.50 target price.
Meridian Mining PLC (MNO:CA): Raymond James raised its target price to $3.00 from $2.75 while maintaining its Outperform rating.
Meridian Mining PLC (MNO:CA): Scotiabank maintained its Outperform rating with a $3.00 target price.
Meridian Mining PLC (MNO:CA): Stifel raised its target price to $4.00 from $3.25 while maintaining its Buy rating.
PMET-Resources Inc. (PMET:CA): Raymond James raised its target price to $13.00 from $12.00 while maintaining its Outperform rating.
Primaris REIT (PMZ.U:CA): BMO maintained its Outperform rating with a $26.00 target price.
Primaris REIT (PMZ-UN:CA): CIBC maintained its Outperform rating with a $26.00 target price.
Primaris REIT (PMZ.U:CA): National Bank maintained its Outperform rating with a $25.50 target price.
Primaris REIT (PMZ-UN:CA): Scotiabank maintained its Sector Perform rating with a $24.00 target price.
Silver X Mining Corp. (AGX:CA): Ventum Financial raised its target price to $2.50 from $1.60; no rating was supplied.
Snowline Gold Corp. (SGD:CA): CIBC maintained its Outperform rating with a $27.00 target price.
Spartan Delta Corp. (SDE:CA): RBC Capital initiated coverage with an Outperform rating and a $17.00 target price.
TC Energy Corporation (TRP:CA): CIBC maintained its Outperform rating with a $103.00 target price.
Thomson Reuters Corp. (TRI:CA): TD Securities maintained its Buy rating with a $200.00 target price.
Tourmaline Oil Corp. (TOU:CA): CIBC maintained its Outperform rating with a $72.50 target price.
Tourmaline Oil Corp. (TOU:CA): TD Securities maintained its Hold rating with a $66.00 target price.
Volatus Aerospace Inc. (FLT:CA): Desjardins Securities initiated coverage with a Buy rating and a $0.90 target price.
WSP-Global Inc. (WSP:CA): CIBC maintained its Outperform rating with a $270.00 target price.
WSP-Global Inc. (WSP:CA): Scotiabank maintained its Outperform rating with a $279.00 target price.
US Analyst Ratings —
Apple Inc. (AAPL): Bank of America assigns a Buy rating and $370 price target.
Absci (ABSI): Needham maintained its Buy rating with a US$11.00 price target.
Acadia Healthcare (ACHC): Leerink Partners raised its price target to US$33.00 from US$30.00 while maintaining a Market Perform rating.
Acadia Pharmaceuticals (ACAD): Oppenheimer maintained its Market Perform rating.
Acadia Realty Trust (AKR): KeyCorp maintained its Overweight rating.
Accelerant (ARX): Raymond James downgraded the stock from Market Perform to Underperform.
Accenture (ACN): BMO Capital Markets raised its price target to US$200.00 from US$150.00 while maintaining a Market Perform rating.
Aduro Clean Technologies (ADUR): HC Wainwright maintained its Buy rating with a US$22.00 price target.
AEVEX (AVEX): Jefferies initiated coverage with a Buy rating and a US$26.00 price target.
Alaska Air Group (ALK): TD Cowen maintained its Buy rating.
Ally Financial (ALLY): Truist Financial lowered its price target to US$50.00 from US$51.00 while maintaining a Buy rating.
Altimmune (ALT): Evercore maintained its Outperform rating.
American Axle & Manufacturing (DCH): Jefferies downgraded the stock from Buy to Hold and lowered its price target to US$7.10 from US$8.25.
American Express (AXP): Truist Financial lowered its price target to US$370.00 from US$375.00 while maintaining a Buy rating.
Amgen (AMGN): Jefferies maintained its Hold rating with a US$410.00 price target.
Amgen (AMGN): Oppenheimer maintained its Outperform rating.
Amneal Pharmaceuticals (AMRX): Oppenheimer initiated coverage with an Outperform rating and a US$27.00 price target.
Amphenol (APH): Sanford C. Bernstein initiated coverage with an Outperform rating and a US$99.00 price target.
Amrize (AMRZ): Deutsche Bank lowered its price target to US$56.00 from US$64.00 while maintaining a Buy rating.
AnaptysBio (ANAB): Leerink Partners lowered its price target to US$81.00 from US$90.00 while maintaining an Outperform rating.
ANI Pharmaceuticals (ANIP): Oppenheimer initiated coverage with a Market Perform rating and a US$85.00 price target.
Apple (AAPL): Bank of America maintained its Buy rating with a US$370.00 price target.
Applied Digital (APLD): UBS initiated coverage with a Buy rating and a US$38.00 price target.
Ardent Health (ARDT): BMO Capital Markets initiated coverage with a Market Perform rating and a US$11.00 price target.
Autoliv (ALV): Wolfe Research downgraded the stock from Outperform to Peer Perform.
AutoZone (AZO): Barclays lowered its price target to US$3,400.00 from US$3,637.00 while maintaining an Overweight rating.
AutoZone (AZO): BMO Capital Markets lowered its price target to US$3,500.00 from US$4,000.00 while maintaining an Outperform rating.
AutoZone (AZO): DA Davidson lowered its price target to US$3,500.00 from US$3,750.00 while maintaining a Buy rating.
AutoZone (AZO): Evercore maintained its Outperform rating.
AutoZone (AZO): Guggenheim lowered its price target to US$3,750.00 from US$4,000.00 while maintaining a Buy rating.
AutoZone (AZO): Mizuho lowered its price target to US$3,000.00 from US$3,200.00 while maintaining a Neutral rating.
AutoZone (AZO): Oppenheimer set a US$3,400.00 price target.
AutoZone (AZO): Raymond James lowered its price target to US$3,700.00 from US$4,000.00 while maintaining a Strong Buy rating.
AutoZone (AZO): Robert W. Baird lowered its price target to US$3,400.00 from US$3,600.00 while maintaining a Neutral rating.
AutoZone (AZO): Roth Capital lowered its price target to US$3,850.00 from US$4,023.00 while maintaining a Buy rating.
AutoZone (AZO): TD Cowen lowered its price target to US$3,400.00 from US$3,500.00 while maintaining a Buy rating.
AutoZone (AZO): Truist Financial lowered its price target to US$3,648.00 from US$3,817.00 while maintaining a Buy rating.
AutoZone (AZO): UBS set a US$3,850.00 price target.
Axsome Therapeutics (AXSM): Truist Financial raised its price target to US$285.00 from US$200.00 while maintaining a Buy rating.
Baldwin Insurance Group (BWIN): Raymond James downgraded the stock from Strong Buy to Underperform.
Bank7 (BSVN): Keefe, Bruyette & Woods raised its price target to US$62.00 from US$56.00 while maintaining an Outperform rating.
Bank7 (BSVN): RBC Capital Markets set a US$62.00 price target.
Belden (BDC): Needham initiated coverage with a Buy rating and a US$140.00 price target.
Beta Bionics (BBNX): Wells Fargo & Company initiated coverage with an Overweight rating and a US$28.00 price target.
Blackstone (BX): UBS maintained its Neutral rating with a US$122.00 price target.
BP (BP): JPMorgan upgraded the stock from Neutral to Overweight.
Bright Horizons Family Solutions (BFAM): Morgan Stanley lowered its price target to US$66.00 from US$68.00 while maintaining an Underweight rating.
Bristol Myers Squibb (BMY): Goldman Sachs maintained its Neutral rating with a US$63.00 price target.
Bullish (BLSH): Canaccord Genuity maintained its Buy rating with a US$45.00 price target.
Canadian National Railway (CNI): Bank of America lowered its price target to US$143.00 from US$146.00 while maintaining a Buy rating.
Cardiol Therapeutics (CRDL): HC Wainwright maintained its Buy rating with a US$9.00 price target.
CarMax (KMX): Morgan Stanley raised its price target to US$47.00 from US$44.00 while maintaining a Cautious rating.
CarMax (KMX): Morgan Stanley raised its price target to US$47.00 from US$44.00 while maintaining an Equal Weight rating.
CBIZ (CBZ): William Blair downgraded the stock from Outperform to Market Perform.
Celldex Therapeutics (CLDX): Leerink Partners raised its price target to US$88.00 from US$70.00 while maintaining an Outperform rating.
Celldex Therapeutics (CLDX): Morgan Stanley raised its price target to US$57.00 from US$50.00 while maintaining an Overweight rating.
Cipher Mining (CIFR): UBS initiated coverage with a Buy rating and a US$23.00 price target.
Citizens Financial Group (CFG): Truist Financial lowered its price target to US$77.00 from US$80.00 while maintaining a Hold rating.
Cognex (CGNX): DA Davidson maintained its Neutral rating with a US$65.00 price target.
Cognex (CGNX): Robert W. Baird lowered its price target to US$70.00 from US$78.00 while maintaining a Neutral rating.
Collegium Pharmaceutical (COLL): Oppenheimer initiated coverage with an Outperform rating and a US$50.00 price target.
Community Health Systems (CYH): BMO Capital Markets initiated coverage with a Market Perform rating and a US$3.00 price target.
Compass Therapeutics (CMPX): Cantor Fitzgerald maintained its Overweight rating.
Compass Therapeutics (CMPX): Citigroup maintained its Market Outperform rating.
Compass Therapeutics (CMPX): Citizens JMP lowered its price target to US$4.00 while maintaining a Market Outperform rating.
Compass Therapeutics (CMPX): Guggenheim lowered its price target to US$4.00 while maintaining a Buy rating.
Compass Therapeutics (CMPX): HC Wainwright lowered its price target to US$12.00 from US$24.00 while maintaining a Buy rating.
Compass Therapeutics (CMPX): Wedbush downgraded the stock from Outperform to Neutral and lowered its price target to US$1.00 from US$5.00.
Constellation Brands (STZ): UBS lowered its price target to US$145.00 from US$168.00 while maintaining a Buy rating.
Core Scientific (CORZ): UBS initiated coverage with a Buy rating and a US$24.00 price target.
CoreWeave (CRWV): UBS initiated coverage with a Buy rating and a US$120.00 price target.
CorMedix (CRMD): Oppenheimer initiated coverage with an Outperform rating and a US$15.00 price target.
Costco Wholesale (COST): BTIG maintained its Buy rating with a US$1,125.00 price target.
Cummins (CMI): JPMorgan lowered its price target to US$600.00 from US$690.00 while maintaining a Neutral rating.
Darden Restaurants (DRI): KeyCorp maintained its Overweight rating.
Domino’s Pizza (DPZ): Guggenheim lowered its price target to US$325.00 from US$440.00 while maintaining a Neutral rating.
Editas Medicine (EDIT): Guggenheim upgraded the stock from Neutral to Buy and set a US$5.00 price target.
Elastic (ESTC): Cantor Fitzgerald maintained its Neutral rating with a US$100.00 price target.
Enanta Pharmaceuticals (ENTA): HC Wainwright maintained its Buy rating with a US$20.00 price target.
Enhanced Group (ENHA): Cantor Fitzgerald initiated coverage with an Overweight rating and a US$4.00 price target.
EQT (EQT): Citigroup raised its price target to US$68.00 from US$67.00 while maintaining a Buy rating.
Ero Copper (ERO): Canadian Imperial Bank of Commerce maintained its Neutral rating.
Fastly (FSLY): Bank of America raised its price target to US$22.00 from US$20.00 while maintaining an Underperform rating.
Fastly (FSLY): DA Davidson raised its price target to US$23.00 from US$21.00 while maintaining a Neutral rating.
Fastly (FSLY): Evercore maintained its Outperform rating.
Fastly (FSLY): Freedom Broker raised its price target to US$37.00 from US$32.00 while maintaining a Buy rating.
Fastly (FSLY): Raymond James maintained its Outperform rating.
Fastly (FSLY): RBC Capital Markets maintained its Sector Perform rating with a US$25.00 price target.
Fifth Third Bancorp (FITB): Truist Financial lowered its price target to US$63.00 from US$64.00 while maintaining a Buy rating.
FOX (FOXA): Guggenheim maintained its Buy rating with a US$85.00 price target.
Franklin BSP Realty Trust (FBRT): Citigroup maintained its Market Outperform rating.
Franklin BSP Realty Trust (FBRT): UBS set a US$10.00 price target.
GE Aerospace (GE): Jefferies lowered its price target to US$435.00 from US$455.00 while maintaining a Buy rating.
General Dynamics (GD): Sanford C. Bernstein lowered its price target to US$407.00 from US$421.00 while maintaining a Market Perform rating.
Getty Realty (GTY): Citigroup maintained its Market Outperform rating.
Getty Realty (GTY): Deutsche Bank set a US$39.00 price target.
Graphic Packaging (GPK): JPMorgan upgraded the stock from Neutral to Overweight and lowered its price target to US$11.50 from US$12.50.
Graphic Packaging (GPK): RBC Capital Markets set a US$11.50 price target.
Guardian Pharmacy Services (GRDN): KeyBanc Capital Markets initiated coverage with an Overweight rating and a US$52.00 price target.
Haleon (HLN): Jefferies maintained its Buy rating.
HCA Healthcare (HCA): BMO Capital Markets initiated coverage with an Outperform rating and a US$495.00 price target.
Hexcel (HXL): RBC Capital Markets maintained its Outperform rating with a US$115.00 price target.
HubSpot (HUBS): FBN Securities initiated coverage with a Sector Perform rating and a US$230.00 price target.
Huntington Bancshares (HBAN): Truist Financial lowered its price target to US$19.00 from US$20.00 while maintaining a Buy rating.
Huntington Ingalls Industries (HII): Sanford C. Bernstein lowered its price target to US$327.00 from US$341.00 while maintaining a Market Perform rating.
Hut 8 (HUT): UBS initiated coverage with a Buy rating and a US$143.00 price target.
Immunovant (IMVT): UBS maintained its Buy rating.
Innoviva (INVA): Oppenheimer initiated coverage with an Outperform rating and a US$35.00 price target.
International Paper (IP): JPMorgan raised its price target to US$62.00 from US$61.00 while maintaining an Overweight rating.
KB Home (KBH): Bank of America lowered its price target to US$54.00 from US$56.00 while maintaining a Neutral rating.
KB Home (KBH): Barclays lowered its price target to US$49.00 from US$57.00 while maintaining an Overweight rating.
KB Home (KBH): Citigroup maintained its Outperform rating.
KB Home (KBH): Citizens JMP lowered its price target to US$70.00 from US$77.00 while maintaining a Market Outperform rating.
KB Home (KBH): Evercore set a US$59.00 price target.
KB Home (KBH): RBC Capital Markets lowered its price target to US$50.00 from US$53.00 while maintaining a Sector Perform rating.
KB Home (KBH): RBC Capital Markets maintained its Market Perform rating.
KB Home (KBH): Truist Financial lowered its price target to US$50.00 from US$55.00 while maintaining a Hold rating.
KB Home (KBH): UBS maintained its Buy rating.
KeyCorp (KEY): Truist Financial lowered its price target to US$23.00 from US$24.00 while maintaining a Hold rating.
KinderCare Learning Companies (KLC): Morgan Stanley lowered its price target to US$2.00 from US$2.50 while maintaining an Underweight rating.
Knight-Swift Transportation (KNX): Bank of America lowered its price target to US$92.00 from US$98.00 while maintaining a Buy rating.
Kymera Therapeutics (KYMR): Piper Sandler maintained its Overweight rating with a US$140.00 price target.
L3Harris Technologies (LHX): Sanford C. Bernstein lowered its price target to US$346.00 from US$365.00 while maintaining an Outperform rating.
Lakefront Biotherapeutics (LKFT): RBC Capital Markets upgraded the stock from Sector Perform to Outperform and raised its price target to US$45.00 from US$26.00.
Levi Strauss & Co. (LEVI): UBS maintained its Buy rating.
Lexeo Therapeutics (LXEO): Leerink Partners maintained its Outperform rating with a US$15.00 price target.
Ligand Pharmaceuticals (LGND): Citigroup raised its price target to US$397.00 from US$390.00 while maintaining a Buy rating.
Lumentum (LITE): Rosenblatt Securities maintained its Buy rating with a US$1,300.00 price target.
M&T Bank (MTB): Truist Financial lowered its price target to US$250.00 from US$268.00 while maintaining a Hold rating.
Madrigal Pharmaceuticals (MDGL): Citigroup initiated coverage with a Buy rating and a US$725.00 price target.
Magnolia Oil & Gas (MGY): Siebert Williams Shank upgraded the stock from Hold to Buy and raised its price target to US$32.00 from US$30.00.
Magnolia Oil & Gas (MGY): Williams Trading set a US$32.00 price target.
Marvell Technology (MRVL): Seaport Research Partners initiated coverage with a Buy rating and a US$270.00 price target.
Maze Therapeutics (MAZE): Citigroup initiated coverage with a Buy rating and a US$50.00 price target.
Maze Therapeutics (MAZE): Wedbush maintained its Outperform rating with a US$48.00 price target.
Medline (MDLN): William Blair maintained its Outperform rating.
MercadoLibre (MELI): New Street Research initiated coverage with a Buy rating and a US$2,450.00 price target.
Meta Platforms (META): Cantor Fitzgerald raised its price target to US$860.00 from US$680.00 while maintaining an Overweight rating.
Meta Platforms (META): KeyCorp raised its price target to US$900.00 from US$780.00 while maintaining an Overweight rating.
Meta Platforms (META): UBS maintained its Overweight rating.
Micron Technology (MU): Citigroup raised its price target to US$1,300.00 from US$1,150.00 while maintaining a Buy rating.
Micron Technology (MU): UBS maintained its Buy rating.
Micron Technology (MU): Wells Fargo & Company lowered its price target to US$1,400.00 from US$1,525.00 while maintaining an Overweight rating.
Microsoft (MSFT): Stifel Nicolaus upgraded the stock from Hold to Buy and raised its price target to US$575.00 from US$530.00.
National Health Investors (NHI): BMO Capital Markets maintained its Outperform rating.
Nektar Therapeutics (NKTR): Wedbush lowered its price target to US$50.00 from US$80.00 while maintaining a Neutral rating.
Neptune Insurance (NP): Deutsche Bank maintained its Buy rating.
Nike (NKE): Barclays maintained its Overweight rating and lowered its price target to US$48.00 from US$52.00.
Nike (NKE): BTIG maintained its Buy rating with a US$55.00 price target.
Nike (NKE): Oppenheimer lowered its price target to US$52.00 from US$60.00 while maintaining an Outperform rating.
Northrop Grumman (NOC): Sanford C. Bernstein lowered its price target to US$620.00 from US$653.00 while maintaining a Market Perform rating.
ON (ONON): BTIG maintained its Buy rating with a US$60.00 price target.
ON (ONON): Citigroup maintained its Buy rating.
ON (ONON): Needham raised its price target to US$40.00 from US$37.00 while maintaining a Buy rating.
ON (ONON): UBS maintained its Buy rating.
onsemi (ON): Seaport Research Partners initiated coverage with a Buy rating and a US$100.00 price target.
Oric Pharmaceuticals (ORIC): BTIG initiated coverage with a Buy rating and a US$26.00 price target.
Pacira BioSciences (PCRX): Oppenheimer initiated coverage with an Outperform rating and a US$32.00 price target.
Packaging Corporation of America (PKG): JPMorgan raised its price target to US$320.00 from US$312.00 while maintaining an Overweight rating.
Palantir Technologies (PLTR): Rosenblatt Securities maintained its Buy rating with a US$225.00 price target.
Palisade Bio (PALI): HC Wainwright maintained its Buy rating with a US$7.00 price target.
PepsiCo (PEP): BNP Paribas Exane lowered its price target to US$161.00 from US$183.00 while maintaining an Outperform rating.
Petroleo Brasileiro S.A.- Petrobras (PBR): UBS raised its price target to US$23.00 from US$22.00 while maintaining a Buy rating.
PG&E (PCG): UBS downgraded the stock from Buy to Neutral and lowered its price target to US$14.00 from US$19.00.
Pharming Group (PHAR): Canaccord Genuity set a US$38.00 price target.
Philip Morris International (PM): UBS raised its price target to US$192.00 from US$182.00 while maintaining a Neutral rating.
Philip Morris International (PM): UBS raised its price target to US$193.00 from US$182.00 while maintaining a Neutral rating.
Pulse Biosciences (PLSE): BTIG initiated coverage with a Buy rating and a US$70.00 price target.
Quoin Pharmaceuticals (QNRX): Lake Street Capital initiated coverage with a Buy rating and a US$20.00 price target.
Rapport Therapeutics (RAPP): Citigroup maintained its Market Outperform rating.
Rapport Therapeutics (RAPP): UBS set a US$80.00 price target.
RB Global (RBA): RBC Capital Markets maintained its Outperform rating with a US$152.00 price target.
Realty Income (O): Scotiabank downgraded the stock from Sector Outperform to Sector Perform and set a US$59.00 price target.
Regions Financial (RF): Truist Financial lowered its price target to US$31.00 from US$34.00 while maintaining a Hold rating.
Rentokil Initial (RTO): Investec upgraded the stock to Buy.
Roblox (RBLX): Needham raised its price target to US$55.00 from US$50.00 while maintaining a Buy rating.
Royal Caribbean Cruises (RCL): BMO Capital Markets maintained its Outperform rating with a US$370.00 price target.
Royal Caribbean Cruises (RCL): Sanford C. Bernstein maintained its Outperform rating.
Royal Caribbean Cruises (RCL): UBS maintained its Buy rating.
RTX (RTX): Sanford C. Bernstein lowered its price target to US$223.00 from US$232.00 while maintaining a Market Perform rating.
Rubrik (RBRK): Robert W. Baird raised its price target to US$139.00 from US$130.00 while maintaining an Outperform rating.
RXO (RXO): Susquehanna upgraded the stock from Negative to Neutral and lowered its price target to US$19.00 from US$20.00.
RXO (RXO): UBS set a US$19.00 price target.
Semtech (SMTC): Seaport Research Partners initiated coverage with a Buy rating and a US$200.00 price target.
Shopify (SHOP): Wedbush maintained its Outperform rating with a US$176.00 price target.
Silvaco Group (SVCO): Rosenblatt Securities maintained its Buy rating with a US$14.00 price target.
SiTime (SITM): Seaport Research Partners initiated coverage with a Neutral rating.
SK hynix (SKHY): Wolfe Research maintained its Outperform rating with a US$250.00 price target.
Smurfit Westrock (SW): JPMorgan raised its price target to US$69.00 from US$68.00 while maintaining an Overweight rating.
Sprouts Farmers Market (SFM): UBS maintained its Neutral rating.
Summit Therapeutics (SMMT): HC Wainwright maintained its Neutral rating.
Summit Therapeutics (SMMT): UBS maintained its Neutral rating.
Sunrise Realty Trust (SUNS): New Street Research upgraded the stock from Sell to Neutral.
TE Connectivity (TEL): Sanford C. Bernstein initiated coverage with an Outperform rating and a US$243.00 price target.
Telix Pharmaceuticals (TLX): Wedbush maintained its Outperform rating with a US$22.00 price target.
Tenet Healthcare (THC): BMO Capital Markets initiated coverage with a Market Perform rating and a US$265.00 price target.
TeraWulf (WULF): UBS initiated coverage with a Buy rating and a US$24.00 price target.
Tetra Technologies (TTI): Stifel Nicolaus lowered its price target to US$12.00 from US$13.00 while maintaining a Buy rating.
Teva Pharmaceutical Industries (TEVA): Oppenheimer initiated coverage with an Outperform rating and a US$50.00 price target.
The Goldman Sachs Group (GS): Citigroup lowered its price target to US$1,050.00 from US$1,200.00 while maintaining a Neutral rating.
Thor Industries (THO): Robert W. Baird lowered its price target to US$80.00 from US$90.00 while maintaining a Neutral rating.
Thor Industries (THO): Roth Capital maintained its Neutral rating with a US$74.00 price target.
Toro (TTC): Oppenheimer initiated coverage with an Outperform rating and a US$120.00 price target.
TotalEnergies (TTE): JPMorgan downgraded the stock from Overweight to Neutral.
TriSalus Life Sciences (TLSI): Guggenheim set a US$12.00 price target.
TriSalus Life Sciences (TLSI): HC Wainwright raised its price target to US$12.00 from US$11.00 while maintaining a Buy rating.
TriSalus Life Sciences (TLSI): Stifel Nicolaus set a US$12.00 price target.
UiPath (PATH): Needham maintained its Buy rating with a US$22.00 price target.
UiPath (PATH): RBC Capital Markets lowered its price target to US$15.00 from US$17.00 while maintaining a Sector Perform rating.
UiPath (PATH): RBC Capital Markets maintained its Outperform rating.
UiPath (PATH): TD Cowen maintained its Hold rating with a US$16.00 price target.
UiPath (PATH): Truist Financial lowered its price target to US$14.00 from US$17.00 while maintaining a Hold rating.
UiPath (PATH): UBS lowered its price target to US$15.00 from US$19.00 while maintaining a Neutral rating.
UiPath (PATH): UBS maintained its Buy rating.
Valero Energy (VLO): Goldman Sachs raised its price target to US$457.00 from US$365.00 while maintaining a Buy rating.
Vanda Pharmaceuticals (VNDA): Oppenheimer initiated coverage with an Outperform rating and a US$10.00 price target.
Viatris (VTRS): Oppenheimer initiated coverage with an Outperform rating and a US$25.00 price target.
Viavi Solutions (VIAV): Rosenblatt Securities maintained its Buy rating with a US$70.00 price target.
Viavi Solutions (VIAV): Stifel Nicolaus set a US$65.00 price target.
Viking Therapeutics (VKTX): Truist Financial raised its price target to US$87.00 from US$83.00 while maintaining a Buy rating.
Wave Life Sciences (WVE): JPMorgan resumed coverage with a Neutral rating and no stated price target.
Weatherford International (WFRD): UBS lowered its price target to US$116.00 from US$120.00 while maintaining a Buy rating.
Willdan Group (WLDN): Wedbush maintained its Outperform rating with a US$130.00 price target.
Wix.com (WIX): Needham raised its price target to US$95.00 from US$80.00 while maintaining a Buy rating.
STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.